Federal budget cuts have created "a climate of anxiety" among medical researchers, says Maximilian F. Konig, a rheumatologist ...

Deucravacitinib met its primary endpoint of more than 20% improvement in ACR20 response among patients with psoriatic ...

Arthritis awareness emphasizes early detection of arthritis, a condition affecting joints, bones, and muscles. Recognizing ...

Metabolic syndrome is common in psoriatic arthritis and is a known risk factor for worse symptoms and poor treatment outcomes. This study sought to explore the syndrome's role in a more precisely ...

Objective To evaluate the efficacy and safety of an oral selective tyrosine kinase 2 (TYK2) inhibitor, deucravacitinib, in patients with active psoriatic arthritis (PsA). Methods In this double-blind, ...

According to the American College of Rheumatology and National Psoriasis Foundation, your treatment strategy should depend on how PsA affects your body and the severity of your symptoms. If your skin ...

If you spend enough time sitting at your desk or slouching on the couch, your back will inevitably pay the price, regardless ...

Psoriatic disease is a long-term (chronic) disease with, thus far, no known cure. The good news, however, is that there are ...

Dr. Michael Garshick discusses recently published recommendations for cardiovascular risk screening for patients with ...

Former Emmerdale star Adam Thomas has been open about his health battles in recent years and now has told fans that his life ...

New research emphasizes the importance of adequate-and possibly higher than currently recommended-protein intake for ...

A new consensus from the National Psoriasis Foundation outlines a clear benchmark for remission to improve treatment decisions and patient outcomes.